Cancer NetworkOriginal article
<![CDATA[CELMoD-Based Maintenance Deepens Responses After ASCT in Multiple Myeloma]]>
Phase 2positiveiberdomidedaratumumabPositive
AI Analysis
Summary
In the Phase 2 IBEX trial, iberdomide combined with subcutaneous daratumumab as post-transplant maintenance therapy improved MRD status in multiple myeloma patients. This positive Phase 2 data supports the use of CELMoD-based regimens in the maintenance setting after autologous stem cell transplantation.
Clinical Trial Data
Phase
2
Primary Endpoint
Met
Outcome Details
Iberdomide plus subcutaneous daratumumab post-transplant maintenance improved MRD status in multiple myeloma patients
Importance:6/10
Sentiment:
0.70
multiple myelomaphase 2 trialIBEX trialmaintenance therapyASCTMRDCELMoD
Read the original article
Published by Cancer Network on September 26, 2026 1:00 PM